nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—ALB—acquired immunodeficiency syndrome	0.208	1	CbGaD
Celecoxib—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0516	0.103	CbGbCtD
Celecoxib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0474	0.095	CbGbCtD
Celecoxib—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.0399	0.08	CbGbCtD
Celecoxib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.02	0.04	CbGbCtD
Celecoxib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0191	0.0383	CbGbCtD
Celecoxib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0167	0.0334	CbGbCtD
Celecoxib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0157	0.0314	CbGbCtD
Celecoxib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0157	0.0314	CbGbCtD
Celecoxib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0153	0.0306	CbGbCtD
Celecoxib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0143	0.0287	CbGbCtD
Celecoxib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0143	0.0287	CbGbCtD
Celecoxib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0142	0.0284	CbGbCtD
Celecoxib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0142	0.0284	CbGbCtD
Celecoxib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.013	0.026	CbGbCtD
Celecoxib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.013	0.026	CbGbCtD
Celecoxib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0122	0.0245	CbGbCtD
Celecoxib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0119	0.0238	CbGbCtD
Celecoxib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0112	0.0224	CbGbCtD
Celecoxib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0109	0.0218	CbGbCtD
Celecoxib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0215	CbGbCtD
Celecoxib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0215	CbGbCtD
Celecoxib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0103	0.0207	CbGbCtD
Celecoxib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00983	0.0197	CbGbCtD
Celecoxib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00983	0.0197	CbGbCtD
Celecoxib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0097	0.0194	CbGbCtD
Celecoxib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00912	0.0183	CbGbCtD
Celecoxib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00912	0.0183	CbGbCtD
Celecoxib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00825	0.0165	CbGbCtD
Celecoxib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00825	0.0165	CbGbCtD
Celecoxib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00712	0.0143	CbGbCtD
Celecoxib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00691	0.0139	CbGbCtD
Celecoxib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00625	0.0125	CbGbCtD
Celecoxib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00625	0.0125	CbGbCtD
Celecoxib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.006	0.012	CbGbCtD
Celecoxib—CA6—saliva—acquired immunodeficiency syndrome	0.00547	0.0852	CbGeAlD
Celecoxib—ORM1—saliva—acquired immunodeficiency syndrome	0.00291	0.0454	CbGeAlD
Celecoxib—PDPK1—retina—acquired immunodeficiency syndrome	0.00215	0.0336	CbGeAlD
Celecoxib—MAPK14—blood plasma—acquired immunodeficiency syndrome	0.0021	0.0328	CbGeAlD
Celecoxib—PDPK1—lymphoid tissue—acquired immunodeficiency syndrome	0.00153	0.0239	CbGeAlD
Celecoxib—PDPK1—digestive system—acquired immunodeficiency syndrome	0.00151	0.0236	CbGeAlD
Celecoxib—PDPK1—blood—acquired immunodeficiency syndrome	0.00144	0.0225	CbGeAlD
Celecoxib—PDPK1—spinal cord—acquired immunodeficiency syndrome	0.00139	0.0216	CbGeAlD
Celecoxib—PDPK1—vagina—acquired immunodeficiency syndrome	0.00134	0.0208	CbGeAlD
Celecoxib—CA4—nerve—acquired immunodeficiency syndrome	0.00131	0.0204	CbGeAlD
Celecoxib—PDPK1—lung—acquired immunodeficiency syndrome	0.00126	0.0197	CbGeAlD
Celecoxib—PDPK1—nervous system—acquired immunodeficiency syndrome	0.00117	0.0182	CbGeAlD
Celecoxib—PDPK1—central nervous system—acquired immunodeficiency syndrome	0.00113	0.0176	CbGeAlD
Celecoxib—ABCC4—blood plasma—acquired immunodeficiency syndrome	0.00107	0.0168	CbGeAlD
Celecoxib—MAPK14—skin of body—acquired immunodeficiency syndrome	0.00101	0.0158	CbGeAlD
Celecoxib—PDPK1—brain—acquired immunodeficiency syndrome	0.000894	0.0139	CbGeAlD
Celecoxib—PDPK1—lymph node—acquired immunodeficiency syndrome	0.000864	0.0135	CbGeAlD
Celecoxib—CA9—digestive system—acquired immunodeficiency syndrome	0.000829	0.0129	CbGeAlD
Celecoxib—CA2—blood plasma—acquired immunodeficiency syndrome	0.000819	0.0128	CbGeAlD
Celecoxib—MAPK14—lymphoid tissue—acquired immunodeficiency syndrome	0.000819	0.0128	CbGeAlD
Celecoxib—MAPK14—digestive system—acquired immunodeficiency syndrome	0.000809	0.0126	CbGeAlD
Celecoxib—MAPK14—blood—acquired immunodeficiency syndrome	0.00077	0.012	CbGeAlD
Celecoxib—MAPK14—bone marrow—acquired immunodeficiency syndrome	0.000745	0.0116	CbGeAlD
Celecoxib—MAPK14—spinal cord—acquired immunodeficiency syndrome	0.000742	0.0116	CbGeAlD
Celecoxib—CA14—spinal cord—acquired immunodeficiency syndrome	0.000722	0.0113	CbGeAlD
Celecoxib—MAPK14—vagina—acquired immunodeficiency syndrome	0.000714	0.0111	CbGeAlD
Celecoxib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000693	0.0108	CbGeAlD
Celecoxib—PTGS2—endothelium—acquired immunodeficiency syndrome	0.000681	0.0106	CbGeAlD
Celecoxib—MAPK14—lung—acquired immunodeficiency syndrome	0.000675	0.0105	CbGeAlD
Celecoxib—MAPK14—nervous system—acquired immunodeficiency syndrome	0.000625	0.00975	CbGeAlD
Celecoxib—CA12—digestive system—acquired immunodeficiency syndrome	0.000613	0.00957	CbGeAlD
Celecoxib—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000605	0.00943	CbGeAlD
Celecoxib—MAPK14—central nervous system—acquired immunodeficiency syndrome	0.000602	0.00939	CbGeAlD
Celecoxib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000528	0.00824	CbGeAlD
Celecoxib—CA5B—blood—acquired immunodeficiency syndrome	0.000524	0.00818	CbGeAlD
Celecoxib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00052	0.00811	CbGeAlD
Celecoxib—CA12—lung—acquired immunodeficiency syndrome	0.000512	0.00799	CbGeAlD
Celecoxib—CA5B—vagina—acquired immunodeficiency syndrome	0.000486	0.00758	CbGeAlD
Celecoxib—MAPK14—brain—acquired immunodeficiency syndrome	0.000478	0.00746	CbGeAlD
Celecoxib—CA12—nervous system—acquired immunodeficiency syndrome	0.000474	0.0074	CbGeAlD
Celecoxib—CA14—brain—acquired immunodeficiency syndrome	0.000465	0.00725	CbGeAlD
Celecoxib—ORM1—blood—acquired immunodeficiency syndrome	0.000464	0.00723	CbGeAlD
Celecoxib—MAPK14—lymph node—acquired immunodeficiency syndrome	0.000462	0.0072	CbGeAlD
Celecoxib—CA5B—lung—acquired immunodeficiency syndrome	0.00046	0.00717	CbGeAlD
Celecoxib—CA12—central nervous system—acquired immunodeficiency syndrome	0.000457	0.00712	CbGeAlD
Celecoxib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000449	0.007	CbGeAlD
Celecoxib—CA2—retina—acquired immunodeficiency syndrome	0.000449	0.007	CbGeAlD
Celecoxib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000447	0.00697	CbGeAlD
Celecoxib—CA5B—nervous system—acquired immunodeficiency syndrome	0.000426	0.00664	CbGeAlD
Celecoxib—ABCC4—digestive system—acquired immunodeficiency syndrome	0.000413	0.00645	CbGeAlD
Celecoxib—CA5B—central nervous system—acquired immunodeficiency syndrome	0.00041	0.00639	CbGeAlD
Celecoxib—ORM1—lung—acquired immunodeficiency syndrome	0.000407	0.00634	CbGeAlD
Celecoxib—CA2—skin of body—acquired immunodeficiency syndrome	0.000394	0.00614	CbGeAlD
Celecoxib—ABCC4—blood—acquired immunodeficiency syndrome	0.000394	0.00614	CbGeAlD
Celecoxib—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000381	0.00594	CbGeAlD
Celecoxib—CA4—digestive system—acquired immunodeficiency syndrome	0.00038	0.00592	CbGeAlD
Celecoxib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000376	0.00587	CbGeAlD
Celecoxib—CA12—brain—acquired immunodeficiency syndrome	0.000363	0.00566	CbGeAlD
Celecoxib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000362	0.00565	CbGeAlD
Celecoxib—CA4—blood—acquired immunodeficiency syndrome	0.000362	0.00564	CbGeAlD
Celecoxib—CA4—bone marrow—acquired immunodeficiency syndrome	0.00035	0.00546	CbGeAlD
Celecoxib—CA4—spinal cord—acquired immunodeficiency syndrome	0.000349	0.00544	CbGeAlD
Celecoxib—ABCC4—lung—acquired immunodeficiency syndrome	0.000345	0.00538	CbGeAlD
Celecoxib—CA5B—brain—acquired immunodeficiency syndrome	0.000325	0.00507	CbGeAlD
Celecoxib—ABCC4—nervous system—acquired immunodeficiency syndrome	0.00032	0.00498	CbGeAlD
Celecoxib—CA2—lymphoid tissue—acquired immunodeficiency syndrome	0.000319	0.00497	CbGeAlD
Celecoxib—CA4—lung—acquired immunodeficiency syndrome	0.000317	0.00495	CbGeAlD
Celecoxib—CA2—digestive system—acquired immunodeficiency syndrome	0.000315	0.00491	CbGeAlD
Celecoxib—CA5B—lymph node—acquired immunodeficiency syndrome	0.000314	0.0049	CbGeAlD
Celecoxib—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.000308	0.0048	CbGeAlD
Celecoxib—CA2—blood—acquired immunodeficiency syndrome	0.0003	0.00468	CbGeAlD
Celecoxib—CA4—nervous system—acquired immunodeficiency syndrome	0.000294	0.00458	CbGeAlD
Celecoxib—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000291	0.00453	CbGeAlD
Celecoxib—CA2—bone marrow—acquired immunodeficiency syndrome	0.00029	0.00453	CbGeAlD
Celecoxib—CA2—spinal cord—acquired immunodeficiency syndrome	0.000289	0.00451	CbGeAlD
Celecoxib—CA4—central nervous system—acquired immunodeficiency syndrome	0.000283	0.00441	CbGeAlD
Celecoxib—CA2—vagina—acquired immunodeficiency syndrome	0.000278	0.00434	CbGeAlD
Celecoxib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000278	0.00434	CbGeAlD
Celecoxib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000266	0.00416	CbGeAlD
Celecoxib—CA2—lung—acquired immunodeficiency syndrome	0.000263	0.0041	CbGeAlD
Celecoxib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000254	0.00396	CbGeAlD
Celecoxib—ALB—brain—acquired immunodeficiency syndrome	0.000252	0.00394	CbGeAlD
Celecoxib—ABCC4—brain—acquired immunodeficiency syndrome	0.000244	0.00381	CbGeAlD
Celecoxib—ALB—lymph node—acquired immunodeficiency syndrome	0.000244	0.0038	CbGeAlD
Celecoxib—CA2—nervous system—acquired immunodeficiency syndrome	0.000244	0.0038	CbGeAlD
Celecoxib—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000236	0.00368	CbGeAlD
Celecoxib—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000235	0.00367	CbGeAlD
Celecoxib—CA2—central nervous system—acquired immunodeficiency syndrome	0.000235	0.00366	CbGeAlD
Celecoxib—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000233	0.00363	CbGeAlD
Celecoxib—CA4—brain—acquired immunodeficiency syndrome	0.000225	0.0035	CbGeAlD
Celecoxib—PTGS2—blood—acquired immunodeficiency syndrome	0.000222	0.00346	CbGeAlD
Celecoxib—CA4—lymph node—acquired immunodeficiency syndrome	0.000217	0.00338	CbGeAlD
Celecoxib—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000214	0.00334	CbGeAlD
Celecoxib—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000213	0.00333	CbGeAlD
Celecoxib—PTGS2—vagina—acquired immunodeficiency syndrome	0.000205	0.0032	CbGeAlD
Celecoxib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000203	0.00317	CbGeAlD
Celecoxib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.0002	0.00312	CbGeAlD
Celecoxib—PTGS2—lung—acquired immunodeficiency syndrome	0.000194	0.00303	CbGeAlD
Celecoxib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000194	0.00302	CbGeAlD
Celecoxib—CYP2D6—blood—acquired immunodeficiency syndrome	0.00019	0.00297	CbGeAlD
Celecoxib—CA2—brain—acquired immunodeficiency syndrome	0.000186	0.0029	CbGeAlD
Celecoxib—CA2—lymph node—acquired immunodeficiency syndrome	0.00018	0.00281	CbGeAlD
Celecoxib—PTGS2—nervous system—acquired immunodeficiency syndrome	0.00018	0.0028	CbGeAlD
Celecoxib—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000173	0.0027	CbGeAlD
Celecoxib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000157	0.00245	CbGeAlD
Celecoxib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000155	0.00241	CbGeAlD
Celecoxib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000151	0.00236	CbGeAlD
Celecoxib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000149	0.00232	CbGeAlD
Celecoxib—PTGS2—brain—acquired immunodeficiency syndrome	0.000137	0.00214	CbGeAlD
Celecoxib—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000133	0.00207	CbGeAlD
Celecoxib—CYP2D6—brain—acquired immunodeficiency syndrome	0.000118	0.00184	CbGeAlD
Celecoxib—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	8.08e-05	0.0032	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.07e-05	0.0032	CbGpPWpGaD
Celecoxib—MAPK14—Signalling to RAS—IL6—acquired immunodeficiency syndrome	7.94e-05	0.00315	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.79e-05	0.00309	CbGpPWpGaD
Celecoxib—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	7.66e-05	0.000377	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	7.65e-05	0.00303	CbGpPWpGaD
Celecoxib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	7.64e-05	0.000376	CcSEcCtD
Celecoxib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	7.64e-05	0.000376	CcSEcCtD
Celecoxib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	7.63e-05	0.000375	CcSEcCtD
Celecoxib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	7.62e-05	0.000375	CcSEcCtD
Celecoxib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	7.61e-05	0.000375	CcSEcCtD
Celecoxib—Pruritus—Stavudine—acquired immunodeficiency syndrome	7.6e-05	0.000374	CcSEcCtD
Celecoxib—Asthenia—Abacavir—acquired immunodeficiency syndrome	7.59e-05	0.000374	CcSEcCtD
Celecoxib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	7.59e-05	0.000374	CcSEcCtD
Celecoxib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000373	CcSEcCtD
Celecoxib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000373	CcSEcCtD
Celecoxib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000373	CcSEcCtD
Celecoxib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	7.55e-05	0.000372	CcSEcCtD
Celecoxib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	7.55e-05	0.000372	CcSEcCtD
Celecoxib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	7.55e-05	0.000371	CcSEcCtD
Celecoxib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	7.53e-05	0.00037	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.52e-05	0.00037	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IFNG—acquired immunodeficiency syndrome	7.52e-05	0.00298	CbGpPWpGaD
Celecoxib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.5e-05	0.000369	CcSEcCtD
Celecoxib—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.49e-05	0.000369	CcSEcCtD
Celecoxib—Fatigue—Indinavir—acquired immunodeficiency syndrome	7.49e-05	0.000368	CcSEcCtD
Celecoxib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.48e-05	0.000368	CcSEcCtD
Celecoxib—PDPK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.48e-05	0.00297	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.48e-05	0.000368	CcSEcCtD
Celecoxib—CA2—Metabolism—AGPS—acquired immunodeficiency syndrome	7.47e-05	0.00296	CbGpPWpGaD
Celecoxib—Cough—Saquinavir—acquired immunodeficiency syndrome	7.47e-05	0.000368	CcSEcCtD
Celecoxib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	7.46e-05	0.000367	CcSEcCtD
Celecoxib—Constipation—Indinavir—acquired immunodeficiency syndrome	7.43e-05	0.000365	CcSEcCtD
Celecoxib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.42e-05	0.000365	CcSEcCtD
Celecoxib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	7.42e-05	0.000365	CcSEcCtD
Celecoxib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	7.41e-05	0.000365	CcSEcCtD
Celecoxib—CA9—Metabolism—TAT—acquired immunodeficiency syndrome	7.41e-05	0.00294	CbGpPWpGaD
Celecoxib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	7.39e-05	0.000364	CcSEcCtD
Celecoxib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.38e-05	0.000363	CcSEcCtD
Celecoxib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.38e-05	0.000363	CcSEcCtD
Celecoxib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.37e-05	0.000363	CcSEcCtD
Celecoxib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7.37e-05	0.000363	CcSEcCtD
Celecoxib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	7.35e-05	0.000362	CcSEcCtD
Celecoxib—Nausea—Didanosine—acquired immunodeficiency syndrome	7.35e-05	0.000362	CcSEcCtD
Celecoxib—PDPK1—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	7.34e-05	0.00291	CbGpPWpGaD
Celecoxib—Vertigo—Lamivudine—acquired immunodeficiency syndrome	7.34e-05	0.000361	CcSEcCtD
Celecoxib—Syncope—Lamivudine—acquired immunodeficiency syndrome	7.32e-05	0.00036	CcSEcCtD
Celecoxib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	7.32e-05	0.00036	CcSEcCtD
Celecoxib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	7.32e-05	0.00036	CcSEcCtD
Celecoxib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.00036	CcSEcCtD
Celecoxib—Somnolence—Efavirenz—acquired immunodeficiency syndrome	7.29e-05	0.000359	CcSEcCtD
Celecoxib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	7.29e-05	0.000359	CcSEcCtD
Celecoxib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	7.29e-05	0.000359	CcSEcCtD
Celecoxib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	7.29e-05	0.000359	CcSEcCtD
Celecoxib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	7.26e-05	0.000357	CcSEcCtD
Celecoxib—Oedema—Ritonavir—acquired immunodeficiency syndrome	7.26e-05	0.000357	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	7.25e-05	0.00288	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	7.25e-05	0.00287	CbGpPWpGaD
Celecoxib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.24e-05	0.000356	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.24e-05	0.000356	CcSEcCtD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	7.23e-05	0.00287	CbGpPWpGaD
Celecoxib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	7.22e-05	0.000355	CcSEcCtD
Celecoxib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.000353	CcSEcCtD
Celecoxib—PDPK1—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	7.18e-05	0.00284	CbGpPWpGaD
Celecoxib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	7.16e-05	0.000352	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.15e-05	0.000352	CcSEcCtD
Celecoxib—PDPK1—IRS-related events—IL6—acquired immunodeficiency syndrome	7.14e-05	0.00283	CbGpPWpGaD
Celecoxib—Shock—Ritonavir—acquired immunodeficiency syndrome	7.14e-05	0.000352	CcSEcCtD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	7.14e-05	0.00283	CbGpPWpGaD
Celecoxib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	7.13e-05	0.000351	CcSEcCtD
Celecoxib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	7.13e-05	0.000351	CcSEcCtD
Celecoxib—Cough—Lamivudine—acquired immunodeficiency syndrome	7.13e-05	0.000351	CcSEcCtD
Celecoxib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	7.13e-05	0.000351	CcSEcCtD
Celecoxib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	7.12e-05	0.00035	CcSEcCtD
Celecoxib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	7.11e-05	0.00035	CcSEcCtD
Celecoxib—Dizziness—Stavudine—acquired immunodeficiency syndrome	7.1e-05	0.00035	CcSEcCtD
Celecoxib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	7.1e-05	0.000349	CcSEcCtD
Celecoxib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	7.1e-05	0.000349	CcSEcCtD
Celecoxib—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	7.09e-05	0.000349	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	7.08e-05	0.000349	CcSEcCtD
Celecoxib—PDPK1—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	7.08e-05	0.00281	CbGpPWpGaD
Celecoxib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	7.07e-05	0.000348	CcSEcCtD
Celecoxib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	7.07e-05	0.000348	CcSEcCtD
Celecoxib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	7.05e-05	0.000347	CcSEcCtD
Celecoxib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	7.05e-05	0.000347	CcSEcCtD
Celecoxib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000347	CcSEcCtD
Celecoxib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	7.02e-05	0.000345	CcSEcCtD
Celecoxib—PDPK1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.02e-05	0.00278	CbGpPWpGaD
Celecoxib—Constipation—Efavirenz—acquired immunodeficiency syndrome	7.02e-05	0.000345	CcSEcCtD
Celecoxib—Rash—Nevirapine—acquired immunodeficiency syndrome	7.02e-05	0.000345	CcSEcCtD
Celecoxib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	7.01e-05	0.000345	CcSEcCtD
Celecoxib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	7e-05	0.000344	CcSEcCtD
Celecoxib—Dizziness—Abacavir—acquired immunodeficiency syndrome	7e-05	0.000344	CcSEcCtD
Celecoxib—Oedema—Saquinavir—acquired immunodeficiency syndrome	6.99e-05	0.000344	CcSEcCtD
Celecoxib—PDPK1—Disease—CCNT1—acquired immunodeficiency syndrome	6.98e-05	0.00277	CbGpPWpGaD
Celecoxib—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.98e-05	0.000343	CcSEcCtD
Celecoxib—Headache—Nevirapine—acquired immunodeficiency syndrome	6.97e-05	0.000343	CcSEcCtD
Celecoxib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000342	CcSEcCtD
Celecoxib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000342	CcSEcCtD
Celecoxib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000342	CcSEcCtD
Celecoxib—Infection—Saquinavir—acquired immunodeficiency syndrome	6.94e-05	0.000342	CcSEcCtD
Celecoxib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	6.93e-05	0.000341	CcSEcCtD
Celecoxib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.92e-05	0.000341	CcSEcCtD
Celecoxib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.91e-05	0.00034	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.91e-05	0.00034	CcSEcCtD
Celecoxib—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.9e-05	0.00034	CcSEcCtD
Celecoxib—PDPK1—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	6.89e-05	0.00273	CbGpPWpGaD
Celecoxib—PDPK1—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	6.89e-05	0.00273	CbGpPWpGaD
Celecoxib—Shock—Saquinavir—acquired immunodeficiency syndrome	6.87e-05	0.000338	CcSEcCtD
Celecoxib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.87e-05	0.000338	CcSEcCtD
Celecoxib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.87e-05	0.000338	CcSEcCtD
Celecoxib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.85e-05	0.000337	CcSEcCtD
Celecoxib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.85e-05	0.000337	CcSEcCtD
Celecoxib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.84e-05	0.000337	CcSEcCtD
Celecoxib—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.83e-05	0.000336	CcSEcCtD
Celecoxib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.82e-05	0.000336	CcSEcCtD
Celecoxib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	6.8e-05	0.000335	CcSEcCtD
Celecoxib—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.79e-05	0.000334	CcSEcCtD
Celecoxib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.79e-05	0.000334	CcSEcCtD
Celecoxib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.79e-05	0.000334	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.78e-05	0.000334	CcSEcCtD
Celecoxib—Rash—Stavudine—acquired immunodeficiency syndrome	6.77e-05	0.000333	CcSEcCtD
Celecoxib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.77e-05	0.000333	CcSEcCtD
Celecoxib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.77e-05	0.000333	CcSEcCtD
Celecoxib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.76e-05	0.000333	CcSEcCtD
Celecoxib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.76e-05	0.000332	CcSEcCtD
Celecoxib—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.75e-05	0.000332	CcSEcCtD
Celecoxib—MAPK14—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	6.74e-05	0.00267	CbGpPWpGaD
Celecoxib—Headache—Stavudine—acquired immunodeficiency syndrome	6.73e-05	0.000331	CcSEcCtD
Celecoxib—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.73e-05	0.000331	CcSEcCtD
Celecoxib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.72e-05	0.000331	CcSEcCtD
Celecoxib—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.71e-05	0.00033	CcSEcCtD
Celecoxib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.71e-05	0.00033	CcSEcCtD
Celecoxib—MAPK14—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.71e-05	0.00266	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	6.7e-05	0.00266	CbGpPWpGaD
Celecoxib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.7e-05	0.00033	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IL2—acquired immunodeficiency syndrome	6.68e-05	0.00265	CbGpPWpGaD
Celecoxib—Rash—Abacavir—acquired immunodeficiency syndrome	6.67e-05	0.000328	CcSEcCtD
Celecoxib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.67e-05	0.000328	CcSEcCtD
Celecoxib—Oedema—Lamivudine—acquired immunodeficiency syndrome	6.67e-05	0.000328	CcSEcCtD
Celecoxib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.67e-05	0.000328	CcSEcCtD
Celecoxib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.66e-05	0.000328	CcSEcCtD
Celecoxib—Headache—Abacavir—acquired immunodeficiency syndrome	6.63e-05	0.000326	CcSEcCtD
Celecoxib—Infection—Lamivudine—acquired immunodeficiency syndrome	6.62e-05	0.000326	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	6.62e-05	0.00263	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.61e-05	0.000326	CcSEcCtD
Celecoxib—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.61e-05	0.000325	CcSEcCtD
Celecoxib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.61e-05	0.000325	CcSEcCtD
Celecoxib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.57e-05	0.000323	CcSEcCtD
Celecoxib—Shock—Lamivudine—acquired immunodeficiency syndrome	6.56e-05	0.000323	CcSEcCtD
Celecoxib—PDPK1—Immune System—ACTG1—acquired immunodeficiency syndrome	6.55e-05	0.0026	CbGpPWpGaD
Celecoxib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.54e-05	0.000322	CcSEcCtD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	6.54e-05	0.00259	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	6.53e-05	0.00259	CbGpPWpGaD
Celecoxib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.53e-05	0.000321	CcSEcCtD
Celecoxib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.52e-05	0.000321	CcSEcCtD
Celecoxib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.52e-05	0.000321	CcSEcCtD
Celecoxib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.49e-05	0.000319	CcSEcCtD
Celecoxib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.49e-05	0.000319	CcSEcCtD
Celecoxib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.47e-05	0.000319	CcSEcCtD
Celecoxib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.47e-05	0.000319	CcSEcCtD
Celecoxib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.47e-05	0.000318	CcSEcCtD
Celecoxib—MAPK14—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	6.46e-05	0.00256	CbGpPWpGaD
Celecoxib—Somnolence—Ritonavir—acquired immunodeficiency syndrome	6.45e-05	0.000318	CcSEcCtD
Celecoxib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.44e-05	0.000317	CcSEcCtD
Celecoxib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.42e-05	0.000316	CcSEcCtD
Celecoxib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.4e-05	0.000315	CcSEcCtD
Celecoxib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.4e-05	0.000315	CcSEcCtD
Celecoxib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.39e-05	0.000315	CcSEcCtD
Celecoxib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.39e-05	0.000314	CcSEcCtD
Celecoxib—Nausea—Stavudine—acquired immunodeficiency syndrome	6.38e-05	0.000314	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.37e-05	0.000313	CcSEcCtD
Celecoxib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.35e-05	0.000313	CcSEcCtD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	6.34e-05	0.00251	CbGpPWpGaD
Celecoxib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6.32e-05	0.000311	CcSEcCtD
Celecoxib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.31e-05	0.000311	CcSEcCtD
Celecoxib—CA9—Metabolism—AGPS—acquired immunodeficiency syndrome	6.3e-05	0.0025	CbGpPWpGaD
Celecoxib—Nausea—Abacavir—acquired immunodeficiency syndrome	6.29e-05	0.000309	CcSEcCtD
Celecoxib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	6.27e-05	0.000309	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.27e-05	0.000308	CcSEcCtD
Celecoxib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.000308	CcSEcCtD
Celecoxib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	6.24e-05	0.000307	CcSEcCtD
Celecoxib—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.23e-05	0.000307	CcSEcCtD
Celecoxib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.23e-05	0.000307	CcSEcCtD
Celecoxib—Somnolence—Saquinavir—acquired immunodeficiency syndrome	6.21e-05	0.000306	CcSEcCtD
Celecoxib—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.21e-05	0.000306	CcSEcCtD
Celecoxib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.21e-05	0.000305	CcSEcCtD
Celecoxib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.21e-05	0.000305	CcSEcCtD
Celecoxib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.17e-05	0.000304	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	6.17e-05	0.00245	CbGpPWpGaD
Celecoxib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	6.15e-05	0.000303	CcSEcCtD
Celecoxib—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.14e-05	0.000302	CcSEcCtD
Celecoxib—MAPK14—IL6-mediated signaling events—IL6—acquired immunodeficiency syndrome	6.13e-05	0.00243	CbGpPWpGaD
Celecoxib—MAPK14—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.13e-05	0.00243	CbGpPWpGaD
Celecoxib—PDPK1—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	6.11e-05	0.00242	CbGpPWpGaD
Celecoxib—MAPK14—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	6.1e-05	0.00242	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	6.09e-05	0.00241	CbGpPWpGaD
Celecoxib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000299	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000299	CcSEcCtD
Celecoxib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	6.05e-05	0.000298	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000297	CcSEcCtD
Celecoxib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	6.03e-05	0.000297	CcSEcCtD
Celecoxib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.02e-05	0.000296	CcSEcCtD
Celecoxib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.99e-05	0.000295	CcSEcCtD
Celecoxib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.98e-05	0.000294	CcSEcCtD
Celecoxib—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.98e-05	0.000294	CcSEcCtD
Celecoxib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000292	CcSEcCtD
Celecoxib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.94e-05	0.000292	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	5.94e-05	0.00236	CbGpPWpGaD
Celecoxib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.94e-05	0.000292	CcSEcCtD
Celecoxib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.94e-05	0.000292	CcSEcCtD
Celecoxib—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.93e-05	0.000292	CcSEcCtD
Celecoxib—Rash—Zidovudine—acquired immunodeficiency syndrome	5.89e-05	0.00029	CcSEcCtD
Celecoxib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.89e-05	0.00029	CcSEcCtD
Celecoxib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.88e-05	0.000289	CcSEcCtD
Celecoxib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.87e-05	0.000289	CcSEcCtD
Celecoxib—Headache—Zidovudine—acquired immunodeficiency syndrome	5.85e-05	0.000288	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	5.85e-05	0.00232	CbGpPWpGaD
Celecoxib—PDPK1—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	5.82e-05	0.00231	CbGpPWpGaD
Celecoxib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.81e-05	0.000286	CcSEcCtD
Celecoxib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.000285	CcSEcCtD
Celecoxib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.78e-05	0.000285	CcSEcCtD
Celecoxib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.77e-05	0.000284	CcSEcCtD
Celecoxib—PDPK1—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	5.77e-05	0.00229	CbGpPWpGaD
Celecoxib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.76e-05	0.000283	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000283	CcSEcCtD
Celecoxib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000283	CcSEcCtD
Celecoxib—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.74e-05	0.000283	CcSEcCtD
Celecoxib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.74e-05	0.000282	CcSEcCtD
Celecoxib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.74e-05	0.000282	CcSEcCtD
Celecoxib—PDPK1—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	5.73e-05	0.00227	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	5.72e-05	0.00227	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.71e-05	0.000281	CcSEcCtD
Celecoxib—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.7e-05	0.000281	CcSEcCtD
Celecoxib—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	5.68e-05	0.00225	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—CSF2—acquired immunodeficiency syndrome	5.68e-05	0.00225	CbGpPWpGaD
Celecoxib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.63e-05	0.000277	CcSEcCtD
Celecoxib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.61e-05	0.000276	CcSEcCtD
Celecoxib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.55e-05	0.000273	CcSEcCtD
Celecoxib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000273	CcSEcCtD
Celecoxib—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.55e-05	0.000273	CcSEcCtD
Celecoxib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.000272	CcSEcCtD
Celecoxib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.000272	CcSEcCtD
Celecoxib—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.52e-05	0.000272	CcSEcCtD
Celecoxib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.49e-05	0.00027	CcSEcCtD
Celecoxib—Rash—Indinavir—acquired immunodeficiency syndrome	5.48e-05	0.000269	CcSEcCtD
Celecoxib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.47e-05	0.000269	CcSEcCtD
Celecoxib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.45e-05	0.000268	CcSEcCtD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.45e-05	0.00216	CbGpPWpGaD
Celecoxib—Headache—Indinavir—acquired immunodeficiency syndrome	5.44e-05	0.000268	CcSEcCtD
Celecoxib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.43e-05	0.000267	CcSEcCtD
Celecoxib—PDPK1—Immune System—MBL2—acquired immunodeficiency syndrome	5.39e-05	0.00214	CbGpPWpGaD
Celecoxib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.37e-05	0.000264	CcSEcCtD
Celecoxib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.35e-05	0.000263	CcSEcCtD
Celecoxib—MAPK14—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	5.33e-05	0.00211	CbGpPWpGaD
Celecoxib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000261	CcSEcCtD
Celecoxib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.27e-05	0.000259	CcSEcCtD
Celecoxib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.27e-05	0.000259	CcSEcCtD
Celecoxib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.22e-05	0.000257	CcSEcCtD
Celecoxib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.21e-05	0.000256	CcSEcCtD
Celecoxib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.19e-05	0.000255	CcSEcCtD
Celecoxib—Rash—Efavirenz—acquired immunodeficiency syndrome	5.17e-05	0.000255	CcSEcCtD
Celecoxib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.17e-05	0.000254	CcSEcCtD
Celecoxib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.16e-05	0.000254	CcSEcCtD
Celecoxib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000253	CcSEcCtD
Celecoxib—Headache—Efavirenz—acquired immunodeficiency syndrome	5.14e-05	0.000253	CcSEcCtD
Celecoxib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.14e-05	0.000253	CcSEcCtD
Celecoxib—MAPK14—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	5.11e-05	0.00203	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.11e-05	0.00203	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.09e-05	0.00202	CbGpPWpGaD
Celecoxib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.01e-05	0.000247	CcSEcCtD
Celecoxib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.99e-05	0.000246	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	4.98e-05	0.00197	CbGpPWpGaD
Celecoxib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.97e-05	0.000244	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	4.96e-05	0.00197	CbGpPWpGaD
Celecoxib—Rash—Delavirdine—acquired immunodeficiency syndrome	4.95e-05	0.000244	CcSEcCtD
Celecoxib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.95e-05	0.000243	CcSEcCtD
Celecoxib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.94e-05	0.000243	CcSEcCtD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	4.94e-05	0.00196	CbGpPWpGaD
Celecoxib—Headache—Delavirdine—acquired immunodeficiency syndrome	4.92e-05	0.000242	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	4.91e-05	0.00195	CbGpPWpGaD
Celecoxib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.91e-05	0.000242	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	4.91e-05	0.00195	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	4.9e-05	0.00194	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.89e-05	0.00194	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.89e-05	0.00194	CbGpPWpGaD
Celecoxib—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.87e-05	0.00024	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—MBL2—acquired immunodeficiency syndrome	4.81e-05	0.00191	CbGpPWpGaD
Celecoxib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.8e-05	0.000236	CcSEcCtD
Celecoxib—PDPK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.79e-05	0.0019	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.79e-05	0.0019	CbGpPWpGaD
Celecoxib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.78e-05	0.000235	CcSEcCtD
Celecoxib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.78e-05	0.000235	CcSEcCtD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	4.77e-05	0.00189	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.72e-05	0.00187	CbGpPWpGaD
Celecoxib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.72e-05	0.000232	CcSEcCtD
Celecoxib—PDPK1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.69e-05	0.00186	CbGpPWpGaD
Celecoxib—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.66e-05	0.000229	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	4.62e-05	0.00183	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.62e-05	0.00183	CbGpPWpGaD
Celecoxib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.62e-05	0.000227	CcSEcCtD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	4.62e-05	0.00183	CbGpPWpGaD
Celecoxib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000227	CcSEcCtD
Celecoxib—PDPK1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.61e-05	0.00183	CbGpPWpGaD
Celecoxib—Rash—Ritonavir—acquired immunodeficiency syndrome	4.58e-05	0.000225	CcSEcCtD
Celecoxib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.57e-05	0.000225	CcSEcCtD
Celecoxib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.56e-05	0.000224	CcSEcCtD
Celecoxib—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	4.55e-05	0.0018	CbGpPWpGaD
Celecoxib—Headache—Ritonavir—acquired immunodeficiency syndrome	4.55e-05	0.000224	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	4.54e-05	0.0018	CbGpPWpGaD
Celecoxib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.44e-05	0.000219	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.42e-05	0.00175	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.41e-05	0.00175	CbGpPWpGaD
Celecoxib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.41e-05	0.000217	CcSEcCtD
Celecoxib—PDPK1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.41e-05	0.00175	CbGpPWpGaD
Celecoxib—Rash—Saquinavir—acquired immunodeficiency syndrome	4.41e-05	0.000217	CcSEcCtD
Celecoxib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.4e-05	0.000217	CcSEcCtD
Celecoxib—PDPK1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.38e-05	0.00174	CbGpPWpGaD
Celecoxib—Headache—Saquinavir—acquired immunodeficiency syndrome	4.38e-05	0.000215	CcSEcCtD
Celecoxib—PDPK1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.36e-05	0.00173	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.35e-05	0.00172	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.35e-05	0.00172	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.34e-05	0.00172	CbGpPWpGaD
Celecoxib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.31e-05	0.000212	CcSEcCtD
Celecoxib—ABCC4—Hemostasis—IFNA1—acquired immunodeficiency syndrome	4.3e-05	0.00171	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	4.26e-05	0.00169	CbGpPWpGaD
Celecoxib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000209	CcSEcCtD
Celecoxib—PDPK1—Immune System—CCR2—acquired immunodeficiency syndrome	4.22e-05	0.00167	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	4.22e-05	0.00167	CbGpPWpGaD
Celecoxib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.2e-05	0.000207	CcSEcCtD
Celecoxib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.2e-05	0.000207	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.19e-05	0.00166	CbGpPWpGaD
Celecoxib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.18e-05	0.000206	CcSEcCtD
Celecoxib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.15e-05	0.000204	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	4.11e-05	0.00163	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.09e-05	0.00162	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00162	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00162	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00162	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.05e-05	0.0016	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.01e-05	0.00159	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.99e-05	0.00158	CbGpPWpGaD
Celecoxib—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.96e-05	0.000195	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	3.93e-05	0.00156	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—CCNT1—acquired immunodeficiency syndrome	3.91e-05	0.00155	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	3.82e-05	0.00151	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IFNA1—acquired immunodeficiency syndrome	3.8e-05	0.00151	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	3.78e-05	0.0015	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.77e-05	0.00149	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CCR2—acquired immunodeficiency syndrome	3.77e-05	0.00149	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	3.73e-05	0.00148	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	3.71e-05	0.00147	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—ALB—acquired immunodeficiency syndrome	3.7e-05	0.00147	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD79A—acquired immunodeficiency syndrome	3.69e-05	0.00146	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	3.68e-05	0.00146	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	3.67e-05	0.00146	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CXCR4—acquired immunodeficiency syndrome	3.67e-05	0.00145	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	3.65e-05	0.00145	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.64e-05	0.00144	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.62e-05	0.00143	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.61e-05	0.00143	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	3.59e-05	0.00142	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.59e-05	0.00142	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	3.58e-05	0.00142	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	3.52e-05	0.0014	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.45e-05	0.00137	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ACTG1—acquired immunodeficiency syndrome	3.41e-05	0.00135	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	3.39e-05	0.00135	CbGpPWpGaD
Celecoxib—MAPK14—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	3.38e-05	0.00134	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.00134	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.31e-05	0.00131	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	3.3e-05	0.00131	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.28e-05	0.0013	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.26e-05	0.00129	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	3.22e-05	0.00128	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	3.19e-05	0.00127	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	3.19e-05	0.00127	CbGpPWpGaD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	3.17e-05	0.00126	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	3.04e-05	0.0012	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.02e-05	0.0012	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.02e-05	0.0012	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD40LG—acquired immunodeficiency syndrome	3.01e-05	0.00119	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—IL2—acquired immunodeficiency syndrome	3e-05	0.00119	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3e-05	0.00119	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.99e-05	0.00119	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.98e-05	0.00118	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CSF2—acquired immunodeficiency syndrome	2.98e-05	0.00118	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD8A—acquired immunodeficiency syndrome	2.98e-05	0.00118	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.97e-05	0.00118	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.96e-05	0.00117	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.95e-05	0.00117	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.94e-05	0.00117	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.93e-05	0.00116	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.86e-05	0.00113	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	2.86e-05	0.00113	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	2.85e-05	0.00113	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.82e-05	0.00112	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MBL2—acquired immunodeficiency syndrome	2.8e-05	0.00111	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.78e-05	0.0011	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	2.74e-05	0.00109	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.73e-05	0.00108	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.73e-05	0.00108	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	2.58e-05	0.00102	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.57e-05	0.00102	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.57e-05	0.00102	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	2.55e-05	0.00101	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.55e-05	0.00101	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	2.55e-05	0.00101	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.54e-05	0.00101	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.54e-05	0.00101	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CCR5—acquired immunodeficiency syndrome	2.51e-05	0.000996	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.47e-05	0.000981	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.43e-05	0.000962	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	2.42e-05	0.000958	CbGpPWpGaD
Celecoxib—CA14—Metabolism—ALB—acquired immunodeficiency syndrome	2.38e-05	0.000943	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.38e-05	0.000943	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.37e-05	0.00094	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.32e-05	0.000921	CbGpPWpGaD
Celecoxib—CA6—Metabolism—ALB—acquired immunodeficiency syndrome	2.32e-05	0.000919	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—ALB—acquired immunodeficiency syndrome	2.32e-05	0.000919	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	2.32e-05	0.000919	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	2.31e-05	0.000916	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.3e-05	0.000911	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—ALB—acquired immunodeficiency syndrome	2.2e-05	0.00087	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CCR2—acquired immunodeficiency syndrome	2.19e-05	0.00087	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—ALB—acquired immunodeficiency syndrome	2.16e-05	0.000858	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL6—acquired immunodeficiency syndrome	2.04e-05	0.000809	CbGpPWpGaD
Celecoxib—CA12—Metabolism—ALB—acquired immunodeficiency syndrome	2e-05	0.000795	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNA1—acquired immunodeficiency syndrome	1.98e-05	0.000783	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.96e-05	0.000779	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.95e-05	0.000774	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.95e-05	0.000772	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.92e-05	0.000763	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—ALB—acquired immunodeficiency syndrome	1.92e-05	0.000762	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.92e-05	0.000761	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD79A—acquired immunodeficiency syndrome	1.92e-05	0.000761	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.91e-05	0.000756	CbGpPWpGaD
Celecoxib—ABCC4—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.9e-05	0.000753	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.9e-05	0.000751	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.89e-05	0.000749	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.88e-05	0.000745	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	1.88e-05	0.000744	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000706	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IFNG—acquired immunodeficiency syndrome	1.77e-05	0.000702	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000698	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.72e-05	0.000682	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD4—acquired immunodeficiency syndrome	1.71e-05	0.000678	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.62e-05	0.000643	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.61e-05	0.000637	CbGpPWpGaD
Celecoxib—CA4—Metabolism—ALB—acquired immunodeficiency syndrome	1.6e-05	0.000634	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.59e-05	0.000629	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.58e-05	0.000627	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CD4—acquired immunodeficiency syndrome	1.58e-05	0.000626	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000623	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.57e-05	0.000622	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40LG—acquired immunodeficiency syndrome	1.56e-05	0.00062	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.56e-05	0.00062	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—IL2—acquired immunodeficiency syndrome	1.56e-05	0.000618	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CSF2—acquired immunodeficiency syndrome	1.55e-05	0.000613	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD8A—acquired immunodeficiency syndrome	1.55e-05	0.000613	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000611	CbGpPWpGaD
Celecoxib—CA2—Metabolism—ALB—acquired immunodeficiency syndrome	1.53e-05	0.000607	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.52e-05	0.000605	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.52e-05	0.000604	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-B—acquired immunodeficiency syndrome	1.49e-05	0.00059	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000573	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.42e-05	0.000563	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.33e-05	0.000529	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.33e-05	0.000529	CbGpPWpGaD
Celecoxib—CA9—Metabolism—ALB—acquired immunodeficiency syndrome	1.29e-05	0.000512	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.25e-05	0.000494	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.000483	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.16e-05	0.000459	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.12e-05	0.000443	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.06e-05	0.00042	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000403	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000402	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.01e-05	0.000401	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1e-05	0.000396	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—IL6—acquired immunodeficiency syndrome	9.34e-06	0.00037	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL6—acquired immunodeficiency syndrome	9.24e-06	0.000366	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNG—acquired immunodeficiency syndrome	9.2e-06	0.000365	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.14e-06	0.000363	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—acquired immunodeficiency syndrome	8.88e-06	0.000352	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—acquired immunodeficiency syndrome	8.53e-06	0.000338	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	8.34e-06	0.000331	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.25e-06	0.000327	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—acquired immunodeficiency syndrome	8.17e-06	0.000324	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	8.06e-06	0.000319	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.4e-06	0.000293	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.98e-06	0.000237	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.28e-06	0.000209	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	5.24e-06	0.000208	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	4.98e-06	0.000197	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—acquired immunodeficiency syndrome	4.8e-06	0.00019	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.33e-06	0.000132	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.3e-06	0.000131	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.11e-06	0.000123	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	2.83e-06	0.000112	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.17e-06	8.62e-05	CbGpPWpGaD
